Rocket Pharmaceuticals (RCKT) Competitors $3.22 -0.04 (-1.08%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RCKT vs. SDGR, HROW, AMPH, NUVB, WVE, ETNB, TLRY, PGEN, RCUS, and NTLAShould you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Schrodinger (SDGR), Harrow (HROW), Amphastar Pharmaceuticals (AMPH), Nuvation Bio (NUVB), WAVE Life Sciences (WVE), 89BIO (ETNB), Tilray Brands (TLRY), Precigen (PGEN), Arcus Biosciences (RCUS), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Rocket Pharmaceuticals vs. Its Competitors Schrodinger Harrow Amphastar Pharmaceuticals Nuvation Bio WAVE Life Sciences 89BIO Tilray Brands Precigen Arcus Biosciences Intellia Therapeutics Rocket Pharmaceuticals (NASDAQ:RCKT) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment. Which has stronger earnings and valuation, RCKT or SDGR? Schrodinger has higher revenue and earnings than Rocket Pharmaceuticals. Schrodinger is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$258.75M-$2.51-1.28Schrodinger$207.54M6.83-$187.12M-$2.48-7.77 Which has more risk & volatility, RCKT or SDGR? Rocket Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Do analysts recommend RCKT or SDGR? Rocket Pharmaceuticals currently has a consensus target price of $16.73, indicating a potential upside of 418.86%. Schrodinger has a consensus target price of $27.83, indicating a potential upside of 44.48%. Given Rocket Pharmaceuticals' higher probable upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41Schrodinger 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals believe in RCKT or SDGR? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 21.0% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media refer more to RCKT or SDGR? In the previous week, Schrodinger had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for Schrodinger and 3 mentions for Rocket Pharmaceuticals. Schrodinger's average media sentiment score of 1.22 beat Rocket Pharmaceuticals' score of 0.81 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RCKT or SDGR more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Schrodinger's return on equity of -45.70% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -65.11% -55.99% Schrodinger -76.22%-45.70%-24.81% SummarySchrodinger beats Rocket Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCKT vs. The Competition Export to ExcelMetricRocket PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$347.98M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-1.2821.1676.1526.51Price / SalesN/A446.35523.22123.62Price / CashN/A45.4037.1760.46Price / Book0.639.6213.686.29Net Income-$258.75M-$53.28M$3.29B$270.60M7 Day Performance1.42%1.01%0.84%1.95%1 Month Performance5.74%4.58%4.63%6.33%1 Year Performance-85.21%8.35%81.08%25.61% Rocket Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCKTRocket Pharmaceuticals4.7762 of 5 stars$3.22-1.1%$16.73+420.5%-83.1%$349.06MN/A-1.29240Short Interest ↑SDGRSchrodinger3.537 of 5 stars$19.44+1.6%$27.83+43.2%-3.8%$1.41B$207.54M-7.84790Positive NewsHROWHarrow2.9795 of 5 stars$39.77+7.5%$64.67+62.6%-2.5%$1.37B$199.61M0.00180Positive NewsGap UpAMPHAmphastar Pharmaceuticals4.049 of 5 stars$29.26-0.5%$31.60+8.0%-44.2%$1.37B$731.97M10.962,028Positive NewsNUVBNuvation Bio2.7025 of 5 stars$3.48-10.9%$7.50+115.8%+6.5%$1.33B$7.87M0.0060Positive NewsHigh Trading VolumeWVEWAVE Life Sciences4.3882 of 5 stars$7.58-8.6%$20.33+168.2%+14.0%$1.32B$108.30M-8.42240ETNB89BIO2.6305 of 5 stars$8.57-3.4%$28.00+226.7%-2.9%$1.32BN/A0.0040Positive NewsTLRYTilray Brands2.856 of 5 stars$1.12-5.9%$1.94+73.0%-32.2%$1.31B$821.31M0.002,842Positive NewsPGENPrecigen4.5439 of 5 stars$4.16-4.6%$8.25+98.3%+289.1%$1.30B$3.92M-9.90190Positive NewsRCUSArcus Biosciences1.8895 of 5 stars$11.43-6.3%$21.14+85.0%-30.5%$1.30B$258M-3.60500Positive NewsNTLAIntellia Therapeutics4.4569 of 5 stars$11.84-1.8%$29.05+145.4%-43.0%$1.29B$57.88M-2.52600 Related Companies and Tools Related Companies SDGR Competitors HROW Competitors AMPH Competitors NUVB Competitors WVE Competitors ETNB Competitors TLRY Competitors PGEN Competitors RCUS Competitors NTLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RCKT) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
